NATCOPHARM.NS NSE
Natco Pharma Limited
1W: -1.7%
1M: -3.3%
3M: -11.8%
YTD: -2.9%
1Y: -9.0%
3Y: -6.2%
5Y: -13.2%
₹819.00 ($8.50)
-8.50 (-1.03%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
#31
of 98
Drug Manufacturers - Specialty & Generic
Technical Signal Map
3 Bullish
4 Neutral
6 Bearish
NATCOPHARM.NS
$147B
Natco Pharma Limited
BEARISH
-58
MANKIND.NS
$1.0T
Mankind Pharma Limited
BULLISH
+100
LAURUSLABS.NS
$1.1T
Laurus Labs Limited
BULLISH
+82
AUROPHARMA.NS
$965B
Aurobindo Pharma Limited
LEAN BULL
+15
RDY
$1.0T
Dr. Reddy's Laboratories Limited
NEUTRAL
+8
ZYDUSLIFE.NS
$1.1T
Zydus Lifesciences Limited
NEUTRAL
-1
DIVISLAB.NS
$2.5T
Divi's Laboratories Limited
NEUTRAL
-4
ALKEM.NS
$626B
Alkem Laboratories Limited
NEUTRAL
-9
GLENMARK.NS
$675B
Glenmark Pharmaceuticals Limited
BEARISH
-34
TORNTPHARM.NS
$1.8T
Torrent Pharmaceuticals Limited
BEARISH
-68
SUNPHARMA.NS
$4.3T
Sun Pharmaceutical Industries Limited
BEARISH
-84
CIPLA.NS
$1.1T
Cipla Limited
BEARISH
-84
LUPIN.NS
$929B
Lupin Limited
BEARISH
-91
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| NATCOPHARM.NS Natco Pharma Limited | $147B | 12.8 | 16.9 | 14.5 | 36.2 | -8.0 | 5 | BEARISH | -9.0 |
| MANKIND.NS Mankind Pharma Limited | $1.0T | 51.2 | 12.5 | 11.0 | 16.1 | 17.0 | 5 | BULLISH | 2.8 |
| LAURUSLABS.NS Laurus Labs Limited | $1.1T | 98.0 | 18.2 | 17.1 | 15.4 | 22.7 | 7 | BULLISH | 130.0 |
| AUROPHARMA.NS Aurobindo Pharma Limited | $965B | 26.2 | 9.9 | 14.1 | 10.4 | 6.1 | 4 | LEAN BULL | 55.5 |
| RDY Dr. Reddy's Laboratories Limited | $1.0T | 30.4 | 12.2 | 10.7 | 2.9 | 3.6 | 3 | NEUTRAL | -13.7 |
| ZYDUSLIFE.NS Zydus Lifesciences Limited | $1.1T | 25.5 | 19.7 | 18.3 | 16.8 | 16.8 | 2 | NEUTRAL | 15.9 |
| DIVISLAB.NS Divi's Laboratories Limited | $2.5T | 83.9 | 16.2 | 16.7 | 26.5 | 13.2 | 6 | NEUTRAL | 50.8 |
| ALKEM.NS Alkem Laboratories Limited | $626B | 29.0 | 17.8 | 18.2 | 6.6 | 13.5 | 4 | NEUTRAL | -2.4 |
| GLENMARK.NS Glenmark Pharmaceuticals Limited | $675B | 36.6 | 14.1 | 23.6 | 8.0 | 27.8 | 8 | BEARISH | 15.0 |
| TORNTPHARM.NS Torrent Pharmaceuticals Limited | $1.8T | 74.0 | 27.1 | 12.2 | 9.3 | 20.5 | 4 | BEARISH | 31.6 |
| SUNPHARMA.NS Sun Pharmaceutical Industries Limited | $4.3T | 35.7 | 14.7 | 18.6 | 18.6 | 11.2 | 4 | BEARISH | 9.8 |
| CIPLA.NS Cipla Limited | $1.1T | 32.2 | 11.8 | 14.0 | 8.5 | 2.9 | 3 | BEARISH | -13.9 |
| LUPIN.NS Lupin Limited | $929B | 16.8 | 26.9 | 35.1 | 19.5 | 22.8 | 7 | BEARISH | 3.5 |
| NATCOPHARM.NS Natco Pharma Limited | $147B | 12.8 | 16.9 | 14.5 | 36.2 | -8.0 | 5 | BEARISH | -9.0 |
| MANKIND.NS Mankind Pharma Limited | $1.0T | 51.2 | 12.5 | 11.0 | 16.1 | 17.0 | 5 | BULLISH | 2.8 |
| LAURUSLABS.NS Laurus Labs Limited | $1.1T | 98.0 | 18.2 | 17.1 | 15.4 | 22.7 | 7 | BULLISH | 130.0 |
| AUROPHARMA.NS Aurobindo Pharma Limited | $965B | 26.2 | 9.9 | 14.1 | 10.4 | 6.1 | 4 | LEAN BULL | 55.5 |
| RDY Dr. Reddy's Laboratories Limited | $1.0T | 30.4 | 12.2 | 10.7 | 2.9 | 3.6 | 3 | NEUTRAL | -13.7 |
| ZYDUSLIFE.NS Zydus Lifesciences Limited | $1.1T | 25.5 | 19.7 | 18.3 | 16.8 | 16.8 | 2 | NEUTRAL | 15.9 |
| DIVISLAB.NS Divi's Laboratories Limited | $2.5T | 83.9 | 16.2 | 16.7 | 26.5 | 13.2 | 6 | NEUTRAL | 50.8 |
| ALKEM.NS Alkem Laboratories Limited | $626B | 29.0 | 17.8 | 18.2 | 6.6 | 13.5 | 4 | NEUTRAL | -2.4 |
| GLENMARK.NS Glenmark Pharmaceuticals Limited | $675B | 36.6 | 14.1 | 23.6 | 8.0 | 27.8 | 8 | BEARISH | 15.0 |
| TORNTPHARM.NS Torrent Pharmaceuticals Limited | $1.8T | 74.0 | 27.1 | 12.2 | 9.3 | 20.5 | 4 | BEARISH | 31.6 |
| SUNPHARMA.NS Sun Pharmaceutical Industries Limited | $4.3T | 35.7 | 14.7 | 18.6 | 18.6 | 11.2 | 4 | BEARISH | 9.8 |
| CIPLA.NS Cipla Limited | $1.1T | 32.2 | 11.8 | 14.0 | 8.5 | 2.9 | 3 | BEARISH | -13.9 |
| LUPIN.NS Lupin Limited | $929B | 16.8 | 26.9 | 35.1 | 19.5 | 22.8 | 7 | BEARISH | 3.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
NATCOPHARM.NS vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F